AU2004276821A1 - Novel therapeutic targets in cancer - Google Patents

Novel therapeutic targets in cancer Download PDF

Info

Publication number
AU2004276821A1
AU2004276821A1 AU2004276821A AU2004276821A AU2004276821A1 AU 2004276821 A1 AU2004276821 A1 AU 2004276821A1 AU 2004276821 A AU2004276821 A AU 2004276821A AU 2004276821 A AU2004276821 A AU 2004276821A AU 2004276821 A1 AU2004276821 A1 AU 2004276821A1
Authority
AU
Australia
Prior art keywords
antibody
protein
polypeptide
expression
pct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2004276821A
Other languages
English (en)
Inventor
Marc S. Malandro
David W. Morris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Novartis Vaccines and Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines and Diagnostics Inc filed Critical Novartis Vaccines and Diagnostics Inc
Publication of AU2004276821A1 publication Critical patent/AU2004276821A1/en
Assigned to NOVARTIS VACCINES AND DIAGNOSTICS, INC. reassignment NOVARTIS VACCINES AND DIAGNOSTICS, INC. Alteration of Name(s) of Applicant(s) under S113 Assignors: CHIRON CORPORATION
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2565/00—Nucleic acid analysis characterised by mode or means of detection
    • C12Q2565/50—Detection characterised by immobilisation to a surface
    • C12Q2565/501—Detection characterised by immobilisation to a surface being an array of oligonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
AU2004276821A 2003-09-23 2004-09-23 Novel therapeutic targets in cancer Abandoned AU2004276821A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/669,920 2003-09-23
US10/669,920 US20060194265A1 (en) 2001-10-23 2003-09-23 Novel therapeutic targets in cancer
PCT/US2004/031617 WO2005031001A2 (en) 2003-09-23 2004-09-23 Novel therapeutic targets in cancer

Publications (1)

Publication Number Publication Date
AU2004276821A1 true AU2004276821A1 (en) 2005-04-07

Family

ID=34393436

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004276821A Abandoned AU2004276821A1 (en) 2003-09-23 2004-09-23 Novel therapeutic targets in cancer

Country Status (6)

Country Link
US (2) US20060194265A1 (enExample)
EP (1) EP1685157A2 (enExample)
JP (1) JP2009519002A (enExample)
AU (1) AU2004276821A1 (enExample)
CA (1) CA2539709A1 (enExample)
WO (1) WO2005031001A2 (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7892730B2 (en) * 2000-12-22 2011-02-22 Sagres Discovery, Inc. Compositions and methods for cancer
WO2004074321A2 (en) 2003-02-14 2004-09-02 Sagres Discovery, Inc. Therapeutic gpcr targets in cancer
US12110555B2 (en) 2004-12-08 2024-10-08 Cedars-Sinai Medical Center Diagnosis and treatment of inflammatory bowel disease
US11268149B2 (en) 2004-12-08 2022-03-08 Cedars-Sinai Medical Center Diagnosis and treatment of inflammatory bowel disease
US20080206753A1 (en) * 2005-03-04 2008-08-28 The Hospital For Sick Children Methods for Cancer Prognosis
JP2008535856A (ja) * 2005-04-07 2008-09-04 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド 癌の診断、検出および治療におけるｓｅｍａ４ｄ
AU2006235276A1 (en) * 2005-04-07 2006-10-19 Novartis Vaccines And Diagnostics Inc. CACNA1E in cancer diagnosis, detection and treatment
EP1897940A4 (en) * 2005-05-02 2009-04-15 Toray Industries COMPOSITION AND METHOD FOR DIAGNOSIS OF CREAM CANCER AND METASTASIS OF CREAM CANCER
JP2007116905A (ja) * 2005-10-24 2007-05-17 Natl Inst Of Radiological Sciences 放射線治療における副作用発症予測用ポリヌクレオチドおよび放射線治療における副作用発症予測方法
US7655778B2 (en) * 2006-02-28 2010-02-02 Curonix Co., Ltd. SISP-1, a novel p53 target gene and use thereof
CN101496387B (zh) 2006-03-06 2012-09-05 思科技术公司 用于移动无线网络中的接入认证的系统和方法
WO2008066498A1 (en) * 2006-12-01 2008-06-05 Agency For Science, Technology And Research Cancer-related protein kinases
US8652472B2 (en) * 2006-12-05 2014-02-18 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
KR101568049B1 (ko) 2006-12-18 2015-11-11 제넨테크, 인크. 항-ｎｏｔｃｈ3 길항제 항체 및 ｎｏｔｃｈ3-관련 질환의 예방 및 치료에 있어서 그의 용도
US8570373B2 (en) 2007-06-08 2013-10-29 Cisco Technology, Inc. Tracking an object utilizing location information associated with a wireless device
US8797377B2 (en) 2008-02-14 2014-08-05 Cisco Technology, Inc. Method and system for videoconference configuration
US8355041B2 (en) 2008-02-14 2013-01-15 Cisco Technology, Inc. Telepresence system for 360 degree video conferencing
US8319819B2 (en) 2008-03-26 2012-11-27 Cisco Technology, Inc. Virtual round-table videoconference
US8390667B2 (en) 2008-04-15 2013-03-05 Cisco Technology, Inc. Pop-up PIP for people not in picture
EP2313435A4 (en) * 2008-07-01 2012-08-08 Aveo Pharmaceuticals Inc FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) BINDING PROTEINS
US8659637B2 (en) 2009-03-09 2014-02-25 Cisco Technology, Inc. System and method for providing three dimensional video conferencing in a network environment
US8477175B2 (en) 2009-03-09 2013-07-02 Cisco Technology, Inc. System and method for providing three dimensional imaging in a network environment
US8659639B2 (en) 2009-05-29 2014-02-25 Cisco Technology, Inc. System and method for extending communications between participants in a conferencing environment
KR101071219B1 (ko) * 2010-03-12 2011-10-10 가톨릭대학교 산학협력단 간암진단용 ＴＧＦβＲΙΙΙ 유전자의 단일 뉴클레오티드 다형성 마커
US9225916B2 (en) 2010-03-18 2015-12-29 Cisco Technology, Inc. System and method for enhancing video images in a conferencing environment
USD626103S1 (en) 2010-03-21 2010-10-26 Cisco Technology, Inc. Video unit with integrated features
USD628175S1 (en) 2010-03-21 2010-11-30 Cisco Technology, Inc. Mounted video unit
USD626102S1 (en) 2010-03-21 2010-10-26 Cisco Tech Inc Video unit with integrated features
US9313452B2 (en) 2010-05-17 2016-04-12 Cisco Technology, Inc. System and method for providing retracting optics in a video conferencing environment
US8896655B2 (en) 2010-08-31 2014-11-25 Cisco Technology, Inc. System and method for providing depth adaptive video conferencing
US9632088B2 (en) * 2010-09-07 2017-04-25 Memorial Sloan-Kettering Cancer Center Methods and compositions for gamma-secretase assay
US8599934B2 (en) 2010-09-08 2013-12-03 Cisco Technology, Inc. System and method for skip coding during video conferencing in a network environment
US8730297B2 (en) 2010-11-15 2014-05-20 Cisco Technology, Inc. System and method for providing camera functions in a video environment
US8902244B2 (en) 2010-11-15 2014-12-02 Cisco Technology, Inc. System and method for providing enhanced graphics in a video environment
US9338394B2 (en) 2010-11-15 2016-05-10 Cisco Technology, Inc. System and method for providing enhanced audio in a video environment
US8723914B2 (en) 2010-11-19 2014-05-13 Cisco Technology, Inc. System and method for providing enhanced video processing in a network environment
US9111138B2 (en) 2010-11-30 2015-08-18 Cisco Technology, Inc. System and method for gesture interface control
USD678307S1 (en) 2010-12-16 2013-03-19 Cisco Technology, Inc. Display screen with graphical user interface
USD678894S1 (en) 2010-12-16 2013-03-26 Cisco Technology, Inc. Display screen with graphical user interface
USD682864S1 (en) 2010-12-16 2013-05-21 Cisco Technology, Inc. Display screen with graphical user interface
USD682854S1 (en) 2010-12-16 2013-05-21 Cisco Technology, Inc. Display screen for graphical user interface
USD682294S1 (en) 2010-12-16 2013-05-14 Cisco Technology, Inc. Display screen with graphical user interface
USD682293S1 (en) 2010-12-16 2013-05-14 Cisco Technology, Inc. Display screen with graphical user interface
USD678320S1 (en) 2010-12-16 2013-03-19 Cisco Technology, Inc. Display screen with graphical user interface
USD678308S1 (en) 2010-12-16 2013-03-19 Cisco Technology, Inc. Display screen with graphical user interface
JP6159662B2 (ja) 2011-03-01 2017-07-05 イエール ユニバーシティ 胃腸膵神経内分泌新生物（ｇｅｐ−ｎｅｎ）の予測方法
FR2992427A1 (fr) * 2012-06-20 2013-12-27 Assist Publ Hopitaux De Paris Methode de pronostic d'un lymphome et kit pour sa mise en oeuvre
EA031025B1 (ru) 2012-12-21 2018-11-30 Сиэтл Дженетикс, Инк. Антитела против ntb-a и связанные с ними композиции и способы
US20160039877A1 (en) 2013-03-15 2016-02-11 Shenzhen Hightide Biopharmaceutical, Ltd. Compositions and methods of using islet neogenesis peptides and analogs thereof
US9458464B2 (en) 2014-06-23 2016-10-04 The Johns Hopkins University Treatment of neuropathic pain
WO2016084062A1 (en) * 2014-11-25 2016-06-02 Rappaport Family Institute For Research In The Medical Sciences Novel epitope as a target for therapy of inflammatory autoimmune diseases and graft rejection
JP7338970B2 (ja) * 2015-09-17 2023-09-05 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル Ｇａｌｇｔ２遺伝子治療のための方法および物質
EP3282019A1 (en) 2016-08-09 2018-02-14 Medizinische Universität Wien Genotyping and treatment of cancer, in particular chronic lymphocytic leukemia
US11338045B2 (en) 2017-03-17 2022-05-24 Newcastle University Adeno-associated virus vector delivery of a fragment of micro-dystrophin to treat muscular dystrophy
EP4296285A3 (en) 2018-04-30 2024-02-28 Cedars-Sinai Medical Center Methods and systems for selection and treatment of patients with inflammatory diseases
CN120393053A (zh) 2018-06-18 2025-08-01 全国儿童医院研究所 用于治疗肌营养不良的肌肉特异性微小肌营养不良蛋白的腺相关病毒载体递送
JP7604376B2 (ja) 2018-12-28 2024-12-23 バーテックス ファーマシューティカルズ インコーポレイテッド 改変ウロキナーゼ型プラスミノゲンアクティベータポリペプチドおよび使用方法
US12012441B2 (en) 2020-10-26 2024-06-18 Neptune Biosciences Llc Engineered human IL-21 cytokines and methods for using the same
WO2025014844A1 (en) * 2023-07-07 2025-01-16 The Regents Of The University Of California Compositions and methods to treat liver, kidney and cell proliferative diseases and disorders

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6852506B1 (en) * 1996-04-10 2005-02-08 Human Genome Sciences, Inc. Extracellular/epidermal growth factor-like protein
US7321023B2 (en) * 1997-11-07 2008-01-22 Incyte Corporation SP16 protein
US6828097B1 (en) * 2000-05-16 2004-12-07 The Childrens Mercy Hospital Single copy genomic hybridization probes and method of generating same
GB0020953D0 (en) * 2000-08-24 2000-10-11 Smithkline Beecham Biolog Vaccine
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US20030216558A1 (en) * 2000-12-22 2003-11-20 Morris David W. Novel compositions and methods for cancer
US20040072264A1 (en) * 2000-12-22 2004-04-15 Morris David W. Novel compositions and methods for cancer
US20030232334A1 (en) * 2000-12-22 2003-12-18 Morris David W. Novel compositions and methods for cancer
US20040072154A1 (en) * 2000-12-22 2004-04-15 Morris David W. Novel compositions and methods for cancer
US7820447B2 (en) * 2000-12-22 2010-10-26 Sagres Discovery Inc. Compositions and methods for cancer
US7892730B2 (en) * 2000-12-22 2011-02-22 Sagres Discovery, Inc. Compositions and methods for cancer
EP1354065A2 (en) * 2001-01-18 2003-10-22 The Regents of The University of California High through-put cloning of protooncogenes
WO2003008583A2 (en) * 2001-03-02 2003-01-30 Sagres Discovery Novel compositions and methods for cancer
US7171311B2 (en) * 2001-06-18 2007-01-30 Rosetta Inpharmatics Llc Methods of assigning treatment to breast cancer patients
DE60222590T2 (de) * 2001-10-30 2008-06-19 Ortho-Clinical Diagnostics, Inc. Methoden zur feststellung von akute myeloischen leukämie
JP3662897B2 (ja) * 2002-05-31 2005-06-22 株式会社水道技術開発機構 仕切り用弁装置
CA2941594C (en) * 2002-12-20 2021-07-06 Celera Corporation Genetic polymorphisms of the protein receptor c (procr) associated with myocardial infarction, methods of detection and uses thereof
US20070099251A1 (en) * 2005-10-17 2007-05-03 Institute For Systems Biology Tissue-and serum-derived glycoproteins and methods of their use

Also Published As

Publication number Publication date
CA2539709A1 (en) 2005-04-07
WO2005031001A3 (en) 2005-09-01
WO2005031001A2 (en) 2005-04-07
US20060194265A1 (en) 2006-08-31
US20070274990A1 (en) 2007-11-29
JP2009519002A (ja) 2009-05-14
EP1685157A2 (en) 2006-08-02

Similar Documents

Publication Publication Date Title
US7332281B2 (en) Therapeutic targets in cancer
EP2196474A2 (en) Therapeutic targets in cancer
US20070274990A1 (en) Novel Therapeutic Targets in Cancer
US20080039413A1 (en) Novel compositions and methods in cancer
US20050202442A1 (en) Novel therapeutic targets in cancer
US20080274467A1 (en) Novel Therapeutic Targets in Cancer
US20070042385A1 (en) Novel compositions and methods in cancer
US7767387B2 (en) Therapeutic targets in cancer
EP2204376A2 (en) Novel therapeutic targets in cancer
AU2003299897B2 (en) Novel compositions and methods in cancer
EP2058408A2 (en) Therapeutic GPCR targets in cancer
US20090214542A1 (en) Novel therapeutic targets in cancer
US20070281896A1 (en) Novel compositions and methods in cancer
US20070218071A1 (en) Novel therapeutic targets in cancer
EP1773382A2 (en) Novel compositions and methods in cancer

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted